Clinical trial
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent…
NCT00335075 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00335075 |
|---|---|
| Title | Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) |
| Official title | A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma, Astrocytoma |
| Intervention type | Drug |
| Interventions | Temozolomide, Semustine |
| Enrollment | 151 |
| Start date | Mar 2, 2005 |
| Primary completion | Feb 23, 2006 |
| Completion | Feb 23, 2006 |
| First posted | Jun 8, 2006 |
| Last update posted | May 15, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: